MN Wealth Advisors LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

MN Wealth Advisors LLC boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,963 shares of the pharmaceutical company’s stock after acquiring an additional 235 shares during the period. MN Wealth Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,193,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Creative Planning raised its holdings in shares of Vertex Pharmaceuticals by 1.7% in the third quarter. Creative Planning now owns 80,467 shares of the pharmaceutical company’s stock worth $37,424,000 after buying an additional 1,350 shares during the last quarter. NBC Securities Inc. raised its holdings in shares of Vertex Pharmaceuticals by 34.5% in the third quarter. NBC Securities Inc. now owns 160 shares of the pharmaceutical company’s stock worth $74,000 after buying an additional 41 shares during the last quarter. Good Life Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals in the third quarter worth $222,000. Trust Co. of Vermont raised its holdings in shares of Vertex Pharmaceuticals by 21.5% in the third quarter. Trust Co. of Vermont now owns 396 shares of the pharmaceutical company’s stock worth $184,000 after buying an additional 70 shares during the last quarter. Finally, Onyx Bridge Wealth Group LLC purchased a new position in shares of Vertex Pharmaceuticals in the third quarter worth $337,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $459.00 on Friday. The company’s 50-day simple moving average is $435.69 and its 200-day simple moving average is $461.52. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. Sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post -1.94 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on VRTX. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Canaccord Genuity Group upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and increased their price objective for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. StockNews.com lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Finally, Truist Financial increased their price objective on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Ten equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $505.57.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 310 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total value of $142,547.30. Following the transaction, the executive vice president now directly owns 64,021 shares of the company’s stock, valued at approximately $29,438,776.43. This trade represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.